Open AccessEffect of High Bolus Dose Tirofiban on the Inflammatory Response Following Percutaneous Coronary Intervention
Author(s) -
Azar Rabih R.,
Badaoui Georges,
Sarkis Antoine,
Kassab Roland,
Salamé Elie,
Aboujaoudé Simon,
Hamdan Righab,
Barakett Vanda,
Germanos Mirna
Publication year - 2010
Publication title -
clinical cardiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.263
H-Index - 72
eISSN - 1932-8737
pISSN - 0160-9289
DOI - 10.1002/clc.20424
Subject(s) - tirofiban , medicine , conventional pci , bolus (digestion) , percutaneous coronary intervention , cardiology , loading dose , myocardial infarction , pharmacology , anesthesia , interquartile range , gastroenterology
Abstract Background Tirofiban at the bolus dose of 10 µg/kg does not suppress the inflammatory response following percutaneous coronary intervention (PCI). This may be due to less than optimal inhibition of platelet aggregation. High bolus dose tirofiban (25 µg/kg) allows better inhibition of platelet aggregation but its anti‐inflammatory effect remains unknown. Hypothesis High bolus dose tirofiban exhibits anti‐inflammatory activity. Methods A total of 100 patients referred for PCI were randomized to receive high bolus dose tirofiban followed by a 24‐h infusion or a bolus and an infusion of saline. Patients with elevated troponin or with thrombus in the culprit lesion were excluded. Inflammatory markers were measured at baseline and at 24 h. Results Levels of soluble CD40 ligand (sCD40L) were not affected by PCI while those of interleukin‐6 (IL‐6) and of high sensitivity C‐reactive protein (hs‐CRP) significantly increased. Despite inhibiting platelet's aggregation by > 90%, tirofiban did not suppress the rise of IL‐6 and hs‐CRP. Median (interquartile range) elevation of IL‐6 was 0.6 pg/mL (−1.5–3.6) versus 0.4 pg/mL (−0.7–1.8) and that of hs‐CRP was 2.1 mg/L (0.7–5.2) versus 2.4 mg/L (1–4.7) in the tirofiban and the control groups, respectively (p = ns). However, in patients with diabetes mellitus, tirofiban significantly suppressed the rise of hs‐CRP by 65% (p = 0.01), but did not significantly affect the rise of IL‐6. Conclusion In low‐risk patients undergoing PCI, tirofiban did not attenuate the rise of inflammatory markers. However, the significant effect in diabetics suggests that tirofiban may have anti‐inflammatory activity in higher risk patients. Copyright © 2009 Wiley Periodicals, Inc.